1087oefficacy, Safety, and Quality of Life (qol) Data from the Eortc 18071 Phase Iii Trial of Ipilimumab (ipi) versus Placebo after Complete Resection of Stage Iii Melanoma.

A.M.M. Eggermont1, V. Chiarion-Sileni2, J.-. Grob3, R. Dummer4, J.D. Wolchok5, H. Schmidt6, O. Hamid7, C. Robert8, P.A. Ascierto9, J.M. Richards10, C. Lebbé11, V. Ferraresi12, M. Smylie13, J.S. Weber14, M. Maio15, C. Konto16, R. Karra Gurunath17, V. De Pril18, S. Suciu19, A. Testori20 Direction, Gustave Roussy Cancer Campus Grand Paris, Villejuif, FRANCE Melanoma Oncology Unit, IOV-IRCCS, Padua, ITALY Dermatology and Skin Cancers, Hopital de la Timone, Marseille, FRANCE Department of Dermatology, University of Zürich Hospital, Zurich, SWITZERLAND Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA Oncology, Aarhus University Hospital, Aarhus, DENMARK Department of Medical Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA, USA Dermatology, Institut Gustave Roussy, Villejuif, FRANCE Unit of Medical Oncology and Innovative Therapy, Istitute Nazionale Tumori Fondazione "G. Pascale", Naples, ITALY Oncology Hematology, Oncology Specialists S.C., Park Ridge, IL, USA Dermatology, APHP U976, Hôpital Saint-Louis, University Paris 7 Diderot, Paris, FRANCE Department of Medical Oncology, Istituti Fisioterapici Ospitalieri, Rome, ITALY Department of Oncology, Cross Cancer Institute, Edmonton, AB, CANADA Immunology, H Lee Moffitt Cancer Center, Tampa, FL, USA Medical Oncology and Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, ITALY Global Clinical Research Oncology, Bristol-Myers Squibb, Wallingford, CT, USA Melanoma Group, EORTC Headquarters, Brussels, BELGIUM Statistics, Bristol-Myers Squibb, Braine-l’Alleud, BELGIUM Biostatistics, EORTC Headquarters, Brussels, BELGIUM Melanoma Division, European Institute of Oncology, Milan, ITALY